Ranjit Manchanda Selected Research

Salpingectomy

1/2022	Surgical decision making in premenopausal BRCA carriers considering risk-reducing early salpingectomy or salpingo-oophorectomy: a qualitative study.
1/2021	Preventing Ovarian Cancer through early Excision of Tubes and late Ovarian Removal (PROTECTOR): protocol for a prospective non-randomised multi-center trial.
5/2020	Systematic review of acceptability, cardiovascular, neurological, bone health and HRT outcomes following risk reducing surgery in BRCA carriers.
1/2018	Setting the Threshold for Surgical Prevention in Women at Increased Risk of Ovarian Cancer.
10/2017	Persistence of fimbrial tissue on the ovarian surface after salpingectomy.
2/2016	Opportunistic bilateral salpingectomy (OBS) for the prevention of ovarian cancer should be offered in the context of a clinical trial: FOR: There is lack of clarity on a number of key issues.
1/2016	Should Opportunistic Bilateral Salpingectomy (OBS) for Prevention of Ovarian Cancer Be Incorporated Into Routine Care or Offered in the Context of a Clinical Trial?
12/2015	Risk reducing salpingectomy and delayed oophorectomy in high risk women: views of cancer geneticists, genetic counsellors and gynaecological oncologists in the UK.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Ranjit Manchanda Research Topics

Disease

17	Ovarian Neoplasms (Ovarian Cancer) 01/2022 - 12/2015
12	Neoplasms (Cancer) 11/2022 - 02/2012
4	Carcinoma (Carcinomatosis) 04/2021 - 01/2019
3	Breast Neoplasms (Breast Cancer) 01/2018 - 12/2015
2	Endometrial Neoplasms (Endometrial Cancer) 01/2022 - 10/2017
2	Premature Menopause 05/2020 - 12/2015
2	Fallopian Tube Neoplasms 05/2017 - 01/2013
1	Carcinogenesis 01/2022
1	Neoplasm Metastasis (Metastasis) 11/2021
1	Neoplasm Micrometastasis 11/2021
1	Vulvar Neoplasms (Vulvar Cancer) 11/2021
1	Infections 10/2021
1	COVID-19 01/2021
1	Uterine Cervical Neoplasms (Cancer of the Cervix) 10/2017
1	Infertility (Sterility) 12/2015
1	Osteoporosis 12/2015
1	Wounds and Injuries (Trauma) 06/2012
1	Rupture 01/2005
1	Pneumoperitoneum 01/2005
1	Mixed Gonadal Dysgenesis 04/2003
1	Gonadoblastoma 04/2003
1	Metrorrhagia (Spotting) 06/2002

Drug/Important Bio-Agent (IBA)

4	Biomarkers (Surrogate Marker)IBA 10/2020 - 09/2018
2	RacivirIBA 05/2017 - 01/2013
1	VitaminsIBA 11/2022
1	DNA (Deoxyribonucleic Acid)IBA 01/2022
1	Indicators and Reagents (Reagents)IBA 01/2022
1	A-Form DNA (A-DNA)IBA 01/2022
1	Follicle Stimulating Hormone (Follitropin)FDA Link 01/2021
1	AutoantibodiesIBA 07/2020
1	2-methylcyclopentadienyl manganese tricarbonyl (MMT)IBA 10/2018
1	Pharmaceutical PreparationsIBA 01/2018
1	AntigensIBA 05/2017
1	Danazol (Azol)FDA LinkGeneric 06/2002

Therapy/Procedure

9	Salpingo-oophorectomy 01/2022 - 02/2012
8	Ovariectomy (Oophorectomy) 01/2022 - 12/2015
8	Salpingectomy 01/2022 - 12/2015
4	Drug Therapy (Chemotherapy) 04/2021 - 05/2017
2	Hormone Replacement Therapy (Therapy, Hormone Replacement) 01/2022 - 01/2018
2	Mastectomy (Mammectomy) 10/2019 - 11/2017
2	Hysterectomy 10/2017 - 01/2005
1	Cytoreduction Surgical Procedures 01/2022
1	Lymph Node Excision (Lymph Node Dissection) 11/2021
1	Radiotherapy 11/2021
1	Treatment Delay 10/2021
1	Personal Protective Equipment 01/2021
1	Chemoprevention 10/2019
1	Therapeutics 12/2015
1	Diathermy 06/2012
1	Castration 04/2003